TOKYO, JAPAN - March 18, 2021 - Terumo Corporation (TSE: 4543), a global leader in medical technology, and Glooko, a leader in remote patient monitoring software and mobile apps, have announced a technology integration to deliver new diabetes data solutions together globally. The partnership will enable the integration of data from Terumo's diabetes care devices such as MEDISAFE WITHTM insulin patch pump and MEDISAFE Fit SmileTM blood glucose meters into Glooko's diasend® diabetes data management platform.
Available in Europe starting on April 1, 2021, the two companies will first collaborate on the diasend®platform to link with MEDISAFE WITH and MEDISAFE Fit Smile, enabling patients to automatically share their diabetes data with healthcare professionals for clinical evaluation. The solution will allow healthcare professionals to access and visualize their patient's health records such as blood glucose data and insulin dosage, in-person at the clinic or remotely through telehealth.
"We are excited to announce this technology integration with Glooko's diasend® platform. For people living with diabetes, day-to-day management of their glucose levels is crucial. This integration will allow patients and healthcare professionals using Terumo's insulin pumps and blood glucose meters to access and analyze rich data to help them to make more precise treatment decisions for every daily life," commented Hikaru Samejima, President of Terumo's General Hospital Company.
Furthermore, in the near future, Terumo's diabetes care devices will be available to be used together with the diasend® mobile app.
Terumo has been a player in the diabetes market for approximately 40 years, since 1982, providing a wide range of products globally such as insulin injection needles, blood glucose meters and insulin pumps. In November 2020, Terumo obtained CE mark for MEDISAFE WITH, and is preparing for the global product launch. Currently, Glooko's solutions are used in 27 countries, digitally connecting people with diabetes and their healthcare professional teams. This partnership is a significant step forward for patients who use Terumo's technology, as they can benefit from enhanced insights with abundant data to help better understand their Time-in-Range patterns and treatment outcomes.
Russ Johannesson, Chief Executive Officer for Glooko stated, "This partnership with Terumo is significant in providing people with diabetes improved insights to critical glucose and insulin data. Clinicians will be able to provide remote patient monitoring of their patients through data that is synced through our mobile app and combined with Terumo's MEDISAFE devices. Our proven clinical study results have demonstrated improved outcomes when patients adopt our mobile app."
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration. The company's software platforms, Glooko and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers - bringing insights together in one place. Data is easily uploaded - remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. Over 3 million users have benefited from diabetes data insights using Glooko's solutions, which are trusted by world leaders in diabetes care, and used in 27 countries across 20 languages. Learn more at glooko.com.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.